ESTRO 2022 - Abstract Book

S946

Abstract book

ESTRO 2022

Conclusion Our preliminary data show that R2* and IVIM MRIs are feasible on the MRL. This study reveals various trends in the evolution of tumour hypoxia and perfusion fractions in HNC. However, further work requires analyses of geometric and measured signal accuracies and sequence optimisation. Patient recruitment continues to establish the roles of tumour hypoxia and perfusion fraction as predictive biomarkers.

PO-1112 Relationship between weight loss during IMRT and outcomes in patients with head and neck cancer

K. Makita 1,2 , Y. Hamamoto 2 , H. Kanzaki 2 , K. Nagasaki 2 , T. Kido 1

1 Ehime University Graduate School of Medicine, Department of Radiology, Toon, Ehime, Japan; 2 National Hospital Organization Shikoku Cancer Center, Department of Radiation Oncology, Matsuyama, Ehime, Japan Purpose or Objective Weight loss (WL) is often observed during radiotherapy for head and neck squamous carcinoma (HNSCC). Because there is controversy whether WL during radiotherapy for HNSCC affects the treatment outcomes, relationship between WL during radiotherapy and treatment outcomes was examined. Materials and Methods Between January 2011 and December 2020, 85 patients with HNSCC (nasopharynx, 28; oropharynx, 22; hypopharynx, 28; larynx, 7) received intensity-modulated radiation therapy (IMRT) of 66-70 Gy (median, 70 Gy), and were weighted at the start and every week of IMRT treatment. Concurrent chemo/biotherapy was performed in 71 patients. Results Median follow-up time was 29.4 months (range, 4.4-110.5 months). Median WL and percent of WL were 4.8 kg (range, 0- 13.3 kg) and 8.4% (range, 0-18.2%), respectively. Three-year overall survival rates, progression-free survival rates (PFS), and locoregional control rates (LC) were 91%, 72%, and 86%, respectively. There were no statistically significant differences in PFS (HR 1.014; 95%CI 0.371-2.773; p=0.978) and LC (HR 0.427; 95%CI 0.120-1.518; p=0.1884) in patients with or without moderate (5%) WL. In addition, there were also no statistically significant differences in PFS (HR 0.568; 95%CI 0.222-1.455; p=0.239) and LC (HR 0.169; 95%CI 0.021-1.338; p=0.092) in patients with or without severe (10%) WL.

Conclusion Clear relationship between WL during IMRT for HNSCC and treatment outcomes could not be found.

PO-1113 Predictive Factors for Response to Neoadjuvant Chemoradiotherapy for Oral Cavity Cancer

J. von der Grün 1,2 , R. Winkelmann 3 , I. Burck 4 , F. Rödel 1,2 , A. Weigert 5 , C. Brandts 6,2 , C. Issing 7 , P. Thönissen 8 , D. Martin 1,2 , C. Rödel 9,2 , S. Ghanaati 8 , P. Balermpas 9,10 1 University Hospital Frankfurt, Department of Radiotherapy and Oncology, Frankfurt, Germany; 2 German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany; 3 University Hospital Frankfurt, Dr. Senckenbergisches Institute of Pathology, Frankfurt, Germany; 4 University Hospital Frankfurt, Department of Diagnostic and Interventional Radiology, Frankfurt, Germany; 5 University of Frankfurt, Institute of Biochemistry I, Frankfurt, Germany; 6 University Hospital Frankfurt, Department of Medicine, Hematology/Oncology, Frankfurt, Germany; 7 University